Bispecific antibody (BsAb) refers to an antibody molecule that can specifically bind two antigens or two epitopes at the same time. In theory, it can exert synergistic effect of two monoclonal antibodies, which is one of the most popular new drug research and development investment direction in the industry.… Continue Reading Bispecific antibody boom

  At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy

  “Big Pharmaceuticals” has been committed to producing a wide range of innovative drugs for many years. For them, gene therapy may be the place to give birth to the next “miracle.” Gene therapy, as its name implies, is a treatment that replaces defective genes with normal genes and has… Continue Reading Gene therapy is the leader, attracting countless giants to compete!

  On March 7, the New England Journal of Medicine published the results of a Phase I study of BI 655139 in the treatment of generalised pustular psoriasis (GPP). Pustular psoriasis is a rare type of psoriasis, accounting for no more than 1%. It is usually divided into generalized pustular… Continue Reading Boehringer Ingelheim first in class monoclonal antibody is surprisingly effective for rare psoriasis

  In 1998, American scientists Andrew Fire and Craig Mello published a groundbreaking paper in Nature, confirming that double-stranded RNA (dsRNA) is the cause of post-transcriptional gene silencing (PTGS) in nematodes. They call this phenomenon RNA interference (RNAi).   The discovery of RNAi (Fig. 1) explains the confusing gene silencing… Continue Reading The world’s first RNAi drug “born” for 20 years and will “explode” in the next 10 years.

  Drug: metformin Magazine: Nature and its publications Highlights: 1) Metformin + heme inhibits tumor growth in triple negative breast cancer 2) Metformin + BCL-2 inhibitor + PD-1 antibody can significantly prolong the survival of breast cancer mice   Metformin was discovered in 1922 and began clinical application in 1957.… Continue Reading Metformin combined treatment of breast cancer is expected

  Drug: NKG2A antibody Magazine: Cell & Nature Highlights: Cancer immunotherapy has a new target – NKG2A, I / II clinical trial data “giving expectations”, but the future is still unclear In recent years, cancer immunotherapy has achieved unprecedented success, but only a few patients have shown lasting efficacy. Improving… Continue Reading A new target for cancer immunotherapy – NKG2A, the future is unknown

  On March 4, Novartis published a clinical trial of a Phase III study of Cosentyx in the treatment of moderate to severe plaque psoriasis at the 2019 Annual Meeting of the American Academy of Dermatology (AAD2019). The reason for this study is that 441 of the 543 patients with… Continue Reading The third phase of clinical data of Cosynmyx China, a new psoriasis drug, was released for the first time: excellent efficacy and significant benefit

  Drug: CAR-T therapy Magazine: Nature Highlights: A clever design that increases the anti-cancer ability of CAR-T therapy   More and more cancer patients are being treated with CAR-T cell therapy.   CAR, the English full name of Chimeric Antigen Receptor, chimeric antigen receptor, is a kind of “navigation” that… Continue Reading Upgraded version of CAR-T therapy, greatly improved anti-cancer ability

  Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or damaging its function. There is no symptom at the beginning of HIV infection, but as the infection progresses, the immune system begins to weaken. The final stage of infection is the acquired… Continue Reading Can immunotherapy create a miracle to cure AIDS?